Interstitial lung disease associated with drug therapy

British Journal of Cancer

Volumn 91, Issue , 2004, Pages S18-S23

  Camus, P ^a   Kudoh, S ^b   Ebina, M ^c  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Gefitinib ( Iressa ); Interstitial lung disease; NSCLC

Indexed keywords

AMINOSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BLEOMYCIN; BUSULFAN; CARMUSTINE; CYTARABINE; DIURETIC AGENT; ETANERCEPT; FIBRINOLYTIC AGENT; GEFITINIB; GLYCOPROTEIN INHIBITOR; GOLD; INTERFERON; METHOTREXATE; MINOCYCLINE; MITOMYCIN; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG INDUCED DISEASE; EVALUATION; FATALITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; JAPAN; LUNG DIFFUSION; LUNG INFILTRATE; LUNG INJURY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; REVIEW;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; JAPAN; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MIDDLE AGED; QUINAZOLINES; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK FACTORS;

EID: 4944238261     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602063     Document Type: Article

References (24)

1. Akira M, Ishikawa H, Yamamoto S (2002) Drug-induced pneumonitis: thinsectionCT findings in 60 patients. Radiology 224: 852-860
2. AstraZeneca and Iressa Expert Committee (2003) Final report on interstitiallung disease (ILD) related to gefitinib (Iressas Tablet 250)
3. Aviram G, Yu E, Tai P, Lefcoe MS (2001) Computed tomography toassess pulmonary injury associated with concurrent chemo-radiotherapyfor inoperable non-small cell lung cancer. Can Assoc Radiol J 52:385-391
4. Camus P, Foucher P, Bonniaud P, Ask K (2001) Drug-induced infiltrativelung disease. Eur Resp J 18(Suppl 32): 93s-100s
5. Cleverley JR, Screaton NJ, Hiorns MP, Flint JDA, Müller NL (2002) Druginducedlung disease: high-resolution CT and histological findings. ClinRadiol 57: 292 -299
6. Ellis SJ, Cleverley JR, Müller NL (2000) Drug-induced lung disease: highresolutionCT findings. AJR Am J Roentgenol 175: 1019-1024
7. Erasmus JJ, McAdams HP, Rossi SE (2002) Drug-induced lung injury.Semin Roentgenol 37: 72-81
8. ESMO (2003) Minimum clinical recommendations for diagnosis, treatmentand follow-up of non-small-cell lung cancer (NSCLC). Available at http://www.esmo.org/reference/referenceGuidelines/pdf/new_pdf/ESMO_03_NSCLC.pdf Accessed 9/03
9. Forsythe B, Faulkner K (2003a) Clinical experience with gefitinib (‘Iressa’, ZD1839): an overview of safety and tolerability. Lung Cancer 41(Suppl 2):S70-S71, (abstr. O-240)
10. Forsythe B, Faulkner K (2003b) Safety and tolerability of gefitinib (’Iressa’, ZD1839) in advanced NSCLC: overview of clinical experience. Posterpresented at the ERS, Vienna, Austria, September 27-October 1, Posternumber P327
11. Foucher P, Camus P, the GEPPI (2003) Pneumotox on line. The druginducedlung diseases. Available at http://www.pneumotox.com/Accessed10/03
12. Fukuoka M, Kris M, Giaccone G, Lynch T, Nakagawa K, Kelly K, Wolf M, McPartlane A, Kay A, Fandi A (2003) Phase II trials of gefitinib (‘Iressa’, ZD1839): rapid and durable objective responses in patients withadvanced non-small-cell lung cancer (IDEAL 1 and IDEAL 2). LungCancer 41(Suppl 2): S247-S248, (abstr. P-615)
13. Gonzalez-Rothi RJ, Zander DS, Ros PR (1995) Fluoxetine hydrochloride(Prozac)-induced pulmonary disease. Chest 107: 1763-1765
14. Imokawa S, Colby TV, Leslie KO, Helmers RA (2000) Methotrexatepneumonitis: review of the literature and histopathological findings innine patients. Eur Resp J 15: 373-381
15. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T (2003) Severe acute interstitialpneumonia and gefitinib. Lancet 361: 137-139
16. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor ofthe epidermal growth factor receptor tyrosine kinase, in symptomaticpatients with non-small cell lung cancer.A randomized trial. JAMA 290:2149- 2158
17. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T (1996) Phase II trial of docetaxel in previously untreated advanced non-smallcelllung cancer: a Japanese cooperative study. J Clin Oncol 14: 1649-1655
18. Lilly (2003) Gemcitabine prescribing information. Available at http://pi.lilly.com/gemzar.pdf Accessed 4/23/99
19. Merad M, Le Cesne A, Baldeyrou P, Mesurolle B, Le Chevalier T (1997) Docetaxel and interstitial pulmonary injury. Ann Oncol 8: 191- 194
20. Oddo M, Liaudet L, Lepori M, Broccard AF, Schaller MD (2003) Relapsingacute respiratory failure induced by minocycline. Chest 123: 2146-2148
21. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, The Eastern Cooperative Oncology Group (2002) Comparison of four chemotherapy regimens for advanced non-smallcelllung cancer. N Engl J Med 346: 92-98
22. Spickard III A, Hirschmann JV (1994) Exogenous lipoid pneumonia. ArchIntern Med 154: 686-692
23. Wang G-S, Yan K-Y, Perng R-P (2001) Life-threatening hypersensitivitypneumonitis induced by docetaxel (taxotere). Br J Cancer 85: 1247- 1250
24. Yamamoto N, Yamada Y, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Takayama K, Sakamoto T, Hoshida M, Tamura T (2003) A phase Istudy of erlotinib HCI in Japanese patients with various types of solidtumors. Proc Am Soc Clin Oncol 22: 225 (abstr. 903)